Orexo (Group)

http://www.orexo.com

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. *

	Start	1995-01-01 established_pre
	Today	Orexo AB (OMX Nordic List, Mid Cap: ORX)
	Predecessor	Diabact AB
	Industry	drug delivery technology (drug formulation technology)
	Industry 2	diagnostics (medical/biological)
	Person	Sørensen, Nikolaj (Orexo 201110– CCO before Pfizer AB + Boston Consulting Group)
	Person 2	Juuel, Henrik (Orexo 2013Q3– CFO)

	Region	Uppsala
	Country	Sweden
	Street	32A Virdings allé
	City	751 05 Uppsala
	Tel	+46-18-780-8800
	Fax	46-18-780-8888
		Address record changed: 2012-07-22

Basic data	Employees	n. a.
	Currency	SEK
	Cash	91,900,000 (2013-09-30)

		* Document for »About Section«:

		Record changed: 2017-04-01

More documents for Orexo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]